CCM
TRDA icon

CAAS Capital Management’s Entrada Therapeutics TRDA Stock Holding History

CAAS Capital Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,000
Closed -$171K – 924
2021
Q4 		$171K Buy
+10,000
New +$243K ﹤0.01% 681

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

CAAS Capital Management's TRDA Position: Q1 2022 in Review

CAAS Capital Management sold out of Entrada Therapeutics (TRDA) in Q1 2022, closing a stake of 10,000 shares — an estimated $171K sold.

CAAS Capital Management first reported a position in TRDA in Q4 2021 and held it in 1 quarter. The position peaked at $171K in Q4 2021. 48 funds tracked by Wall St. Rank hold TRDA as of Q1 2022.

  • CAAS Capital Management reported no remaining Entrada Therapeutics position as of Q1 2022 after selling out during the quarter.
  • CAAS Capital Management sold 10,000 Entrada Therapeutics shares in Q1 2022, an estimated $171K.
  • CAAS Capital Management first reported a position in Entrada Therapeutics in Q4 2021 and held it in 1 quarter.
  • CAAS Capital Management's Entrada Therapeutics position peaked at $171K in Q4 2021.
  • 48 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2022.

Based on CAAS Capital Management's 13F filing for Q1 2022, filed 13 May 2022.